✦ LIBER ✦

BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin’s lymphoma patients: comparative analysis of efficacy and toxicity

✍ Scribed by Jae-Cheol Jo; Byung Wook Kang; Geundoo Jang; Sun Jin Sym; Sung Sook Lee; Ja Eun Koo; Jong Wook Kim; Shin Kim; Jooryung Huh; Cheolwon Suh

Publisher: Springer
Year: 2007
Tongue: English
Weight: 144 KB
Volume: 87
Category: Article
ISSN: 0939-5555
DOI: 10.1007/s00277-007-0360-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Chemotherapy with rituximab followed by

Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma

✍ Catherine Thieblemont; Daciana Antal; Laurence Lacotte-Thierry; Vincent Delwail; 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB

## Abstract ## BACKGROUND The authors evaluated the efficacy of chemotherapy combined with rituximab followed by high‐dose therapy (HDT) plus autologous stem cell transplantation in patients with mantle cell lymphoma (MCL). ## METHODS This was a retrospective analysis of 34 patients who were tre

Long-term followup of health status in p

Long-term followup of health status in patients with severe rheumatoid arthritis after high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation

✍ Y. K. O. Teng; R. J. Verburg; J. K. Sont; W. B. Van Den Hout; F. C. Breedveld; J 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB 👁 2 views

The hyper-CVAD–rituximab chemotherapy pr

The hyper-CVAD–rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma

✍ D. S. Ritchie; J. F. Seymour; A. P. Grigg; A. W. Roberts; R. Hoyt; S. Thompson; 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 113 KB

A randomized trial of chemotherapy with

A randomized trial of chemotherapy with carmustine, etoposide, cytarabine, and melphalan (BEAM) plus peripheral stem cell transplantation (PBSCT) vs single-agent high-dose chemotherapy followed by BEAM plus PBSCT in patients with relapsed Hodgkin's disease (HD-R2)

✍ J.-P. Glossmann; A. Josting; B. Pfistner; U. Paulus; A. Engert; German Hodgkin's 📂 Article 📅 2002 🏛 Springer 🌐 English ⚖ 90 KB

Efficacy of diverse high-dose regimens f

Efficacy of diverse high-dose regimens followed by autologous peripheral blood stem cell transplantation in consecutive multiple myeloma patients: a single-centre analysis over a 12-year period

✍ P. S. Haas; K. Bauchmüller; A. Kühnemund; J. Finke; G. Ihorst; M. Engelhardt 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 89 KB

Feasibility and toxicity of high-dose th

Feasibility and toxicity of high-dose therapy (HDT) supported by peripheral blood stem cells in elderly patients with multiple myeloma and non-Hodgkin's lymphoma: Survey from a single institution

✍ Massimo Magagnoli; Luca Castagna; Monica Balzarotti; Barbara Sarina; Inna Timofe 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB 👁 2 views